Q1 2025
Released May 8, 2025, before the open
10-Q filed May 8, 2025, 38 days after period end · 0001628280-25-023486
Q1 2025 · 10-Q
Revenue$1.45M$1.45M +146.0% vs Q1 2024−33.4% vs Q4 2024
Net Income-$51.89M-$51.89M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.40-$0.40 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$52,392,000N/M
Operating Cash Flow-$48,857,000N/M
Free Cash Flowderived-$51,279,000N/M
Margins · derived
Operating margin-3603.3%+4576.2 pt vs Q1 2024
Net margin-3568.8%+4174.2 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $1.45M | $591.00K | $0.00 | — |
| Net Income | -$51.89M | -$45.76M | -$39.40M | -$23.84M |
| EPS Diluted | -$0.40 | -$0.44 | -$0.44 | -$1.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR